HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,061,960 | +5.9% | 27,800 | 0.0% | 0.16% | +11.0% |
| Q2 2023 | $1,002,746 | -5.6% | 27,800 | 0.0% | 0.14% | -11.6% |
| Q1 2023 | $1,061,682 | -32.9% | 27,800 | 0.0% | 0.16% | -35.9% |
| Q4 2022 | $1,581,820 | +43.9% | 27,800 | 0.0% | 0.26% | +36.2% |
| Q3 2022 | $1,099,000 | -10.1% | 27,800 | 0.0% | 0.19% | -5.5% |
| Q2 2022 | $1,223,000 | +10.4% | 27,800 | 0.0% | 0.20% | +32.7% |
| Q1 2022 | $1,108,000 | -0.9% | 27,800 | 0.0% | 0.15% | +6.4% |
| Q4 2021 | $1,118,000 | -1.1% | 27,800 | 0.0% | 0.14% | -7.8% |
| Q3 2021 | $1,131,000 | -10.4% | 27,800 | 0.0% | 0.15% | -8.9% |
| Q2 2021 | $1,262,000 | +8.9% | 27,800 | 0.0% | 0.17% | +1.8% |
| Q1 2021 | $1,159,000 | -2.4% | 27,800 | 0.0% | 0.16% | -9.8% |
| Q4 2020 | $1,187,000 | +62.4% | 27,800 | 0.0% | 0.18% | +39.7% |
| Q3 2020 | $731,000 | -1.9% | 27,800 | 0.0% | 0.13% | -6.4% |
| Q2 2020 | $745,000 | +49.0% | 27,800 | 0.0% | 0.14% | +22.8% |
| Q1 2020 | $500,000 | +1.4% | 27,800 | 0.0% | 0.11% | +35.7% |
| Q4 2019 | $493,000 | +38.1% | 27,800 | +20.9% | 0.08% | +29.2% |
| Q3 2019 | $357,000 | -9.6% | 23,000 | 0.0% | 0.06% | -8.5% |
| Q2 2019 | $395,000 | +6.5% | 23,000 | 0.0% | 0.07% | +6.0% |
| Q1 2019 | $371,000 | +49.0% | 23,000 | +35.3% | 0.07% | +28.8% |
| Q4 2018 | $249,000 | -49.3% | 17,000 | -37.0% | 0.05% | -38.1% |
| Q3 2018 | $491,000 | -9.1% | 27,000 | -15.6% | 0.08% | -12.5% |
| Q2 2018 | $540,000 | -21.3% | 32,000 | -8.6% | 0.10% | -21.3% |
| Q1 2018 | $686,000 | -15.3% | 35,000 | -12.5% | 0.12% | -12.9% |
| Q4 2017 | $810,000 | -6.8% | 40,000 | -20.0% | 0.14% | -11.4% |
| Q3 2017 | $869,000 | -53.3% | 50,000 | -65.5% | 0.16% | -55.0% |
| Q2 2017 | $1,859,000 | -1.1% | 145,000 | 0.0% | 0.35% | -1.7% |
| Q1 2017 | $1,879,000 | +31.1% | 145,000 | 0.0% | 0.36% | +25.3% |
| Q4 2016 | $1,433,000 | -18.2% | 145,000 | 0.0% | 0.28% | -21.5% |
| Q3 2016 | $1,752,000 | +40.0% | 145,000 | 0.0% | 0.36% | +36.5% |
| Q2 2016 | $1,251,000 | -21.9% | 145,000 | 0.0% | 0.27% | -22.0% |
| Q1 2016 | $1,601,000 | -36.3% | 145,000 | 0.0% | 0.34% | -33.8% |
| Q4 2015 | $2,513,000 | +647.9% | 145,000 | +480.0% | 0.52% | +605.5% |
| Q3 2015 | $336,000 | – | 25,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |